The University of Cambridge and MedImmune are delighted to launch a collaborative PhD programme in Biomedical Research, commencing in October 2015. This innovative 4 year programme will focus on topical areas of biomedical research falling within the scope of interest of both the University of Cambridge and MedImmune. MedImmune, the global biologics unit of AstraZeneca, is focused on the areas of cardiovascular and metabolic disease, infection, respiratory and inflammatory diseases, oncology and neuroscience.